Seegene Inc.

Seegene Inc. is a globally recognized biotechnology and molecular diagnostics company specializing in multiplex real-time PCR technologies, syndromic testing, infectious disease diagnostics, and molecular automation. Founded in 2000 and headquartered in Seoul, South Korea, the company develops advanced molecular diagnostic solutions that enable healthcare professionals to detect multiple pathogens simultaneously from a single patient sample.

Seegene is internationally known for its proprietary Allplex™, Novaplex™, and STARlet-AIOS™ product lines, which support rapid diagnosis of respiratory infections, sexually transmitted infections (STIs), gastrointestinal diseases, tropical diseases, antimicrobial resistance (AMR), and other infectious conditions. The company’s proprietary DPO™ (Dual Priming Oligonucleotide), TOCE™ (Tagging Oligonucleotide Cleavage and Extension), and MuDT™ (Multiple Detection Temperature) technologies provide high sensitivity, specificity, and multiplex testing capabilities.

Seegene continues to invest heavily in artificial intelligence, laboratory automation, molecular biology, digital diagnostics, and precision medicine. Its manufacturing facilities and research laboratories comply with international quality standards and regulatory requirements established by the US FDA, CE-IVD/IVDR, ISO 13485, and numerous global health authorities.

Through continuous scientific innovation and international collaboration, Seegene has become one of the world’s leading providers of molecular diagnostic technologies, supporting hospitals, laboratories, and public health agencies in improving disease detection and outbreak response.